Welcome to The Early Detection Summit 2023
Earlier detection of disease can revolutionise patient outcomes for a variety of therapeutic areas, significantly reducing mortality rates of diseases such as cancer.
The first of its kind to approach early detection from a cross-disease focus, the Early Detection Summit provides the latest case studies and innovative strategies enabling accelerating early detection – from cancer, to diabetes, to arthritis.
Gain insights from leading pharma, biotech companies and academic researchers facilitating the new age of early detection tools, with a lens on collaborative working to advance research forward.
WHY ATTEND
Understand the key challenges facing the early detection of disease from diagnostic test pitfalls to enhancing clinical trial success.
Devise innovative ways in which we can address and overcome current challenges.
Facilitate collaboration, both across diseases, as well as, across academia and industry to work together in establishing new technologies.
Explore how we can advance clinical trials for more effective research through established partnerships across the industry.
Understand the requirements of healthcare systems to prepare for the implementation of early detection.
Devise a way forward with industry leaders to ensure early detection becomes the new routine reality.
WHO YOU WILL MEET
-
Academia40%
-
Pharma & Drug Developers35%
-
Diagnostic Companies and Solution Providers20%
-
Clinician5%
OUR INDUSTRY LEADING SPEAKERS
Allan Hackshaw
Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Director of the Cancer Research UK & UCL Cancer Trials Centre. He has over 30 years’ experience in the design, conduct, analysis and interpretation of cohort/case-control studies, large real-world data studies, phase I-III clinical trials, and systematic reviews; in several areas including cancer, and tobacco and health. His particular focus has been on adult (mainly cancer) and prenatal screening, as a key investigator on large scale studies, some of which have evaluated new screening tests and policies that later became routine practice. He is a member of the UK National Screening Committee Adult Reference Group, and co-editor of the Journal of Medical Screening. He has published more than 200 journal articles and book chapters, and sole or first author of four textbooks.
Anita Grigoriadis
Anita Grigoriadis is a Reader in Cancer Bioinformatics in the School of Cancer and Pharmaceutical Sciences, the Non-Clinical Deputy Head for the Breast Cancer Now Unit, and
an executive member of the CRUK City of London Centre.
After finishing her degree at the Institute of Molecular Pathology, University of Vienna (Austria), Anita pursued a joint PhD between the Ludwig Institute for Cancer Research, London UK and Faculty of Natural Sciences, Salzburg Austria.
Anita conducted her postdoctoral training on breast cancer genomics with Professor Alan Ashworth at Breakthrough Breast Cancer Centre (London).
In 2008, she joined the Breast Cancer NOW Unit (formerly Breakthrough Breast Cancer Research) at King’s under the leadership of Professor Andrew Tutt and started her own team in 2013. Currently, Anita is a committee member of The Clinical Trial Pathology Advisory Group of the Cellular Molecular Pathology (NCRI programme), and recently the Research Subcommittee of the Pathological Society.
Ashley Eater
Ashley Eater is Head of Business Development and Partnerships, Global Oncology Diagnostics at AstraZeneca, where he leads a team creating partnerships with diagnostic and related companies to increase patient access to oncology medicines worldwide. He recently co-led development of AstraZeneca’s in-market strategy for early detection and screening and is excited about opportunities to improve early detection in underserved tumour types, use of multi-cancer early detection, and strengthening screening in emerging markets and through broad collaboration. Previously Ashley worked in companion diagnostic marketing, development, and in scientific consulting. He has a PhD from the University of Cambridge in Molecular Biology and sits on the board of the Precision Cancer Consortium.
Giovanna Lalli
Simon Leedham
Simon Leedham is Professor of Molecular and Population Genetics University of Oxford and an Honorary Consultant Gastroenterologist at the John Radcliffe Hospital. His research is into the morphogenic signalling pathways that control the intestinal stem cell in homeostasis, regeneration and cancer, and he has published more than 90 peer reviewed papers in journals that include Nature Medicine, Nature Genetics, Cell Stem Cell, Gastroenterology and Gut. Simon’s research has been recognised by the United European Gastroenterology Rising Star award in 2010, the British Society of Gastroenterology Francis Avery Jones research prize in 2015 and the CRUK future leaders prize in 2017. Simon’s clinical work involves the care of patients with familial predisposition towards gastrointestinal cancer and he is Associate Director of the Oxford Centre for Cancer Early Detection.
Dr Emma Woodward
Dr Emma Woodward, Consultant Clinical Geneticist at Saint Mary’s Hospital and Deputy Director of CRUK Manchester University. Dr Woodward’s current research is aimed at understanding the inherited predisposition to cancer, in particular thyroid cancer and also whether structural genomic variants influence cancer predisposition risk. Her clinical work involves the inherited predisposition to adult and paediatric onset cancers.
Dr Eric A. Klein
Eric A. Klein, MD is the Emeritus Andrew C. Novick Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic. Following undergraduate study at Johns Hopkins University, he was a cum laude graduate of the University of Pittsburgh School of Medicine. He subsequently completed residency training in Urology at the Cleveland Clinic and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He joined the staff of the Cleveland Clinic in 1989 and served as a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center. Dr. Klein is currently a Fellow in the Distinguished Careers Institute at Stanford University.
Dr. Klein is a member of numerous professional societies and scientific advisory boards including the Board of Scientific Counselors of the National Cancer Institute, the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons, the Society of Urologic Oncology, the Society of Pelvic Surgeons, the American College of Surgeons, and the American Urological Association. He served as President of the Society of Urologic Oncology from 2009 - 2011.
Dr. Klein’s clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. Under his direction, the Prostate Cancer Research Program has been recognized as “Program of the Year” by the Cleveland Clinic. He has served as Chairman of the Localized Prostate Cancer Committee of the Southwest Oncology Group and was the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 700 papers to the scientific literature, authored or edited 8 books on urologic malignancies, and serves as the Editor-in-Chief of UROLOGY. He has delivered more than 200 invited scientific lectures including 13 named lectureships and has served as a Visiting Professor at more than 60 institutions around the world. Dr. Klein was awarded the F. Mason Sones Innovation Award by the Cleveland Clinic in 2009, The Joe V. Meigs Award by the Society of Pelvic Surgeons in 2013 and 2015, was named the Kidney Foundation of Ohio’s Person of the Year in 2017, and has received 6 Career Achievement Awards including the 2001 Norman K. Probstein Award for Meritorious Contributions to Oncology from the Washington University School of Medicine, a 2014 Presidential Citation from the American Urological Association, the 2014 Huggins Medal from the Society of Urologic Oncology, the 2015 Philip S. Hench Award from the University of Pittsburgh School of Medicine, the 2020 SUO Medal from the Society of Urologic Oncology, and the 2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award from the Urology Care Foundation.
Dr Gwen Murphy
Dr Gwen Murphy earned a PhD in Clinical Medicine from Trinity College Dublin, Ireland, in 2005, and a Masters in Public Health from University College Dublin in 2006. Dr Murphy joined DCEG as an NCI Cancer Prevention Fellow within the Infections and Immunoepidemiology Branch in 2006, where she worked with Dr Charles Rabkin to initiate the NCI International EBV-Gastric Cancer Consortium. During her fellowship she also collaborated with Dr Amanda Cross on a suite of molecular epidemiology studies within the Polyp Prevention Trial. In 2009, Dr Murphy moved to the Nutritional Epidemiology Branch as a Research Fellow, becoming a Staff Scientist in 2012.
Dr Hormuzd Katki
Dr. Hormuzd Katki is a Senior Investigator in the Biostatistics Branch of the US National Cancer Institute. Dr. Katki’s research focuses on all issues related to individualized risk-based approaches to cancer screening, with a focus on cancers of the lung and cervix. His recent research focuses on 3 broad areas. First is improving external validity of epidemiologic/trial analyses and prediction models, by using survey sampling methodology. Second, he leads a team to calculate outcomes from different designs for a potential screening trial of multicancer early detection tests. Finally, he works on enhancing research on underserved populations to promote fairness in prevention, which is an outgrowth of his work on disparities and algorithmic fairness in lung-cancer screening recommendations.
Fiona Carragher
Talisia Quallo
Stephen Duffy
Eleanor Wheeler
DISCOVER THE LINE UP
We're delighted to introduce the Early Detection Summit 2023.
LEARNING approaches to pursue collaboration across industry and academia, advancing early detection into a routine reality
IMPROVING your understanding of biomarkers of disease to advance early diagnosis and overcoming current challenges faced when working with biomarkers such as increased sensitivity and specificity.
BUILDING a way forward to early detection becoming a routine reality through exploring healthcare infrastructure, cost, and an exploration of what comes next.
BE THE FIRST TO SEE THE AGENDA
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact Simon Pickles. Commercial partnership lead: [email protected]
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Amber Wareing, Senior Marketing Manager, [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.